These effects were attenuated by treatment with U0126, a MEK1/2 inhibitor, and AG-1478, an EGFR tyrosine kinase inhibitor [138]. using either genetic or pharmacological approaches to block M3R expression and activation, respectively, attenuates the development and progression of colon cancer. … Continue reading These effects were attenuated by treatment with U0126, a MEK1/2 inhibitor, and AG-1478, an EGFR tyrosine kinase inhibitor [138]